References
- De Franzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus: the Multicenter Metformin Study Group. N Engl J Med 1995; 333(9): 541–9
- The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14): 977–86
- Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329(5): 304–9
- Kuusisto J, Mykkä nen L, Pyö rö lö K, et al. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43(8): 960–7
- Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med 1994; 121(12): 928–35
- Coniff RF, Shapiro JA, Seaton TB. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin- dependent diabetes mellitus. Arch Intern Med 1994; 154(21): 2442–8
- Spengler M, Cagatay M. The use of acarbose in the primary-care setting: evaluation of efficacy and tolerability of acarbose by postmarketing surveillance study. Clin Invest Med 1995; 18(4): 325–31
- American Diabetes Association. Consensus statement: The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1995; 18(11): 510–8